Impacts of Immunotherapy on Patients With Aggressive Thyroid Carcinomas

Alfred King-Yin Lam^{1

2

3}

Affiliations

¹ School of Medicine and Dentistry, Griffith University, Southport, Queensland, Australia.
² Faculty of Medicine, The University of Queensland, Herston, Queensland, Australia.
³ Pathology Queensland, Gold Coast University Hospital, Southport, Queensland, Australia.

Comment

Alfred King-Yin Lam. JAMA Oncol. 2024.

. 2024 Dec 1;10(12):1617-1618.

doi: 10.1001/jamaoncol.2024.4202.

Alfred King-Yin Lam^{1

2

3}

¹ School of Medicine and Dentistry, Griffith University, Southport, Queensland, Australia.
² Faculty of Medicine, The University of Queensland, Herston, Queensland, Australia.
³ Pathology Queensland, Gold Coast University Hospital, Southport, Queensland, Australia.

No abstract available

Comment on

Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid Carcinoma: A Phase 2 Nonrandomized Clinical Trial.
Sehgal K, Pappa T, Shin KY, Schiantarelli J, Liu M, Ricker C, Besson NR, Jones SM, Welsh EL, Pfaff KL, Barletta JA, Park J, Reardon B, Doherty GM, Alexander EK, Rodig SJ, Barbie DA, O'Neill A, Van Allen E, Haddad RI, Lorch JH. Sehgal K, et al. JAMA Oncol. 2024 Dec 1;10(12):1663-1671. doi: 10.1001/jamaoncol.2024.4019. JAMA Oncol. 2024. PMID: 39446365 Clinical Trial.
Anti-Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial.
Cabanillas ME, Dadu R, Ferrarotto R, Gule-Monroe M, Liu S, Fellman B, Williams MD, Zafereo M, Wang JR, Lu C, Ning M, McKinley BA, Woodman SE, Duose D, Gunn GB, Busaidy NL; Rare Tumor Initiative Team. Cabanillas ME, et al. JAMA Oncol. 2024 Dec 1;10(12):1672-1680. doi: 10.1001/jamaoncol.2024.4729. JAMA Oncol. 2024. PMID: 39446377 Free PMC article. Clinical Trial.